SG11202006302TA - Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors - Google Patents

Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Info

Publication number
SG11202006302TA
SG11202006302TA SG11202006302TA SG11202006302TA SG11202006302TA SG 11202006302T A SG11202006302T A SG 11202006302TA SG 11202006302T A SG11202006302T A SG 11202006302TA SG 11202006302T A SG11202006302T A SG 11202006302TA SG 11202006302T A SG11202006302T A SG 11202006302TA
Authority
SG
Singapore
Prior art keywords
ghrelin
goat
inhibitors
acyl transferase
triazolopyrimidine derivatives
Prior art date
Application number
SG11202006302TA
Other languages
English (en)
Inventor
Thomas Trieselmann
Cédrickx Godbout
Christoph Hoenke
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11202006302TA publication Critical patent/SG11202006302TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202006302TA 2018-02-02 2019-01-28 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors SG11202006302TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154831 2018-02-02
PCT/EP2019/051994 WO2019149660A1 (en) 2018-02-02 2019-01-28 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Publications (1)

Publication Number Publication Date
SG11202006302TA true SG11202006302TA (en) 2020-07-29

Family

ID=61157054

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006302TA SG11202006302TA (en) 2018-02-02 2019-01-28 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors

Country Status (21)

Country Link
US (1) US11583532B2 (es)
EP (1) EP3746443B1 (es)
JP (1) JP7083397B2 (es)
KR (1) KR20200118125A (es)
CN (1) CN111683951B (es)
AU (1) AU2019215710A1 (es)
BR (1) BR112020014436A2 (es)
CA (1) CA3087925A1 (es)
CL (1) CL2020001909A1 (es)
CO (1) CO2020009177A2 (es)
CR (1) CR20200329A (es)
EA (1) EA202091803A1 (es)
EC (1) ECSP20050797A (es)
IL (1) IL276145A (es)
JO (1) JOP20200187A1 (es)
MA (1) MA51774A (es)
MX (1) MX2020007994A (es)
PE (1) PE20210658A1 (es)
PH (1) PH12020551170A1 (es)
SG (1) SG11202006302TA (es)
WO (1) WO2019149660A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6651054B2 (ja) 2016-08-05 2020-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo−アシルトランスフェラーゼ(goat)阻害薬として使用するためのオキサジアゾロピリジン誘導体
US11583532B2 (en) 2018-02-02 2023-02-21 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors
PE20210174A1 (es) 2018-02-02 2021-01-29 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
TW202202502A (zh) * 2020-03-26 2022-01-16 美商斯諾皮亞生物科學公司 經同位素標記之曲匹地(trapidil)衍生物
IL297929A (en) 2020-05-04 2023-01-01 Volastra Therapeutics Inc Imino sulfanone inhibitors of enpp1
CN115916789A (zh) 2020-05-22 2023-04-04 勃林格殷格翰国际有限公司 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
CN115884974A (zh) 2020-05-22 2023-03-31 勃林格殷格翰国际有限公司 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的方法
WO2021257614A1 (en) * 2020-06-16 2021-12-23 Volastra Therapeutics, Inc. Heterocyclic inhibitors of enpp1
CN115073363B (zh) * 2022-06-16 2024-01-26 宁波申泰生物科技有限公司 一种5-氟-2-甲氧基烟醛及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3338292A1 (de) * 1983-10-21 1985-05-02 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)-pyrimidine und diese enthaltende fungizide
JP2002249492A (ja) 2000-12-22 2002-09-06 Nippon Bayer Agrochem Co Ltd トリアゾロピリミジン類
WO2004082383A1 (en) * 2003-03-17 2004-09-30 Basf Aktiengesellschaft Use of triazolopyrimidines for combating nematode diseases of plants
CN101163404A (zh) * 2005-04-25 2008-04-16 巴斯福股份公司 5-烷基-6-苯基烷基-7-氨基唑并嘧啶的用途、新的唑并嘧啶、其制备方法以及包含它们的组合物
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK3567035T3 (da) 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
CN101720327A (zh) 2007-04-30 2010-06-02 雅培制药有限公司 二酰甘油o-酰基转移酶1型酶的抑制剂
JP2010527951A (ja) 2007-05-24 2010-08-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
FR2933989B1 (fr) 2008-07-16 2013-03-08 Commissariat Energie Atomique Procede de purification de microorganismes presents dans des echantillons liquides
FR2933975B1 (fr) 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
PL2454282T3 (pl) 2009-07-13 2015-08-31 Zealand Pharma As Acylowane analogi glukagonu
US20110078154A1 (en) 2009-09-28 2011-03-31 Accenture Global Services Gmbh Recruitment screening tool
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
KR20140114845A (ko) 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
US9238639B2 (en) 2012-02-24 2016-01-19 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
EP3250569B1 (en) 2015-01-30 2019-01-09 Boehringer Ingelheim International GmbH Aldosterone synthase inhibitors
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2018004947A (es) 2015-10-22 2018-11-09 Cavion Inc Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
JP6651054B2 (ja) 2016-08-05 2020-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo−アシルトランスフェラーゼ(goat)阻害薬として使用するためのオキサジアゾロピリジン誘導体
US10988487B2 (en) 2016-08-29 2021-04-27 Merck Sharp & Dohme Corp. Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
PE20210174A1 (es) 2018-02-02 2021-01-29 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
JP7150032B2 (ja) 2018-02-02 2022-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンo-アシルトランスフェラーゼ(goat)阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
US11583532B2 (en) * 2018-02-02 2023-02-21 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors

Also Published As

Publication number Publication date
CA3087925A1 (en) 2019-08-08
EP3746443B1 (en) 2022-07-06
AU2019215710A1 (en) 2020-07-23
CR20200329A (es) 2020-09-04
ECSP20050797A (es) 2020-09-30
BR112020014436A2 (pt) 2020-12-01
JOP20200187A1 (ar) 2020-07-29
KR20200118125A (ko) 2020-10-14
CN111683951B (zh) 2023-10-13
PE20210658A1 (es) 2021-03-31
CO2020009177A2 (es) 2020-07-31
PH12020551170A1 (en) 2021-05-31
US11583532B2 (en) 2023-02-21
CN111683951A (zh) 2020-09-18
CL2020001909A1 (es) 2020-10-30
EP3746443A1 (en) 2020-12-09
JP2021512115A (ja) 2021-05-13
MX2020007994A (es) 2020-09-09
IL276145A (en) 2020-09-30
US20210038603A1 (en) 2021-02-11
JP7083397B2 (ja) 2022-06-10
WO2019149660A1 (en) 2019-08-08
MA51774A (fr) 2021-05-12
EA202091803A1 (ru) 2020-12-16

Similar Documents

Publication Publication Date Title
IL276145A (en) Triazolopyrimidine history for use as ghrelin O-acyltransferase inhibitors
IL292642A (en) ras inhibitors
IL292643A (en) ras inhibitors
IL292644A (en) ras inhibitors
IL283639A (en) kif18a inhibitors
EP3602905A4 (en) INDICATION OF A PART OF A TIME INTERVAL
IL276137A (en) Heterocyclyl-converted oxadiazolopyridine compounds for use as ghrelin O-acyltransferase inhibitors
RS61937B1 (sr) Oksadiazolopiridin derivati za primenu kao inhibitori grelin o-acil transferaze (goat)
SG11202003194YA (en) Methods for the administration of certain vmat2 inhibitors
IL279662A (en) Methods of administration of certain VMAT2 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
SG11202006080SA (en) Liquid oral formulations for pde v inhibitors
ZA201705675B (en) Ghrelin o-acyl transferase inhibitors
ZA201705678B (en) Ghrelin o-acyl transferase inhibitors
EP3193939A4 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
IL276013A (en) pi4kiiibeta inhibitors
IL277518B1 (en) inhibitors of prmt5
IL268565B (en) A history of pyrazoles as bromodomain inhibitors
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
IL281599A (en) TYK2 kinase inhibitors
IL283112A (en) Lox inhibitors
ZA202100140B (en) Pyridopyrimidinone derivatives for use as axl inhibitors
GB201809295D0 (en) Lox inhibitors
GB201807845D0 (en) Kinase Inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors